Multimodal biomarker panel for early prediction of anastomotic leak after colorectal surgery: from inflammation to ischemia - Summary - MDSpire

Multimodal biomarker panel for early prediction of anastomotic leak after colorectal surgery: from inflammation to ischemia

  • By

  • Yuji Li

  • June 2, 2026

  • 0 min

Share

Objective:

To systematically review the current status and effectiveness of various biomarkers in predicting anastomotic leakage (AL) after colorectal surgery and propose a comprehensive multimodal prediction framework.

Key Findings:
  • Anastomotic leakage has an incidence of 2% to 19% and is associated with significant complications.
  • Traditional diagnostic methods are reactive and often delayed, increasing adverse outcomes.
  • Biomarkers from inflammation, ischemia, microbiome, and tissue repair show potential for early detection of AL.
  • Machine learning algorithms may help integrate diverse data sources, but external validation is lacking.
Interpretation:

The review highlights the fragmentation in existing research on biomarkers for AL, indicating a lack of systematic integration of findings into clinical tools.

Limitations:
  • Existing studies are heterogeneous in endpoints, timing, and methodology, with examples including variations in biomarker types and measurement techniques.
  • Most research is based on small-sample, single-center cohorts with limited external validation.
Conclusion:

A multimodal prediction framework integrating inflammation, ischemia, microbiome, and tissue repair is proposed, emphasizing the urgent need for future research focused on validation and standardization.

Original Source(s)

Multimodal biomarker panel for early prediction of anastomotic leak after colorectal surgery: from inflammation to ischemia

  • by Yuji Li

  • June 2, 2026

Related Content

Brief Prehabilitation Reduced Complications Prior to Gastrectomy

Researchers evaluate a supervised, home-based program combining exercise, nutrition, and psychological support before surgery

Framework Targets Hospital-Onset UTIs

The expert panel outlines surveillance, device management, and diagnostic stewardship strategies to address both catheter-associated and non–catheter-associated infections.

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.